Lipocine


Here’s Why Lipocine (LPCN) Stock Jumped 60% Today

Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Lipocine (LPCN), …

Why Lipocine (LPCNׁ) Saw Its Stock Price Plummet Today

Lipocine (NASDAQ:LPCN) is down 35.5% after receiving a complete response letter (CRL) from the FDA for its testosterone treatment TLANDO.

Lipocine Inc (LPCN) Stock Is Now a “Show Me” Story

Odds of approval for LPCN’s Tlando come May 8th? H.

Lipocine Inc. (LPCN): FDA Panel Gives Thumbs Down to TLANDO, What’s Next?

While Lipocine investors run for the hills following negative advisory committee meeting, Canaccord’s Dewey Steadman still sees a light at the end of the tunnel.

Lipocine Inc (LPCN) Fails to Convince FDA Advisory Committee of TLANDO’s Merit; Shares Decline Over 50%

Lipocine Inc (NASDAQ:LPCN) failed to convince the Food and Drug Administration advisory committee that its phase 3 data testing TLANDO in hypogonadal male …

Bull Believes Lipocine Inc (LPCN) Oral Testosterone Candidate Eventually Approvable, But Not Betting on Today’s FDA Meeting

Canaccord’s Dewey Steadman says once LPCN’s Tlando gets the safety data it needs in hand to impress the FDA, a green light will flash.

Analysts Bullish on Biotech Giants: Keryx Biopharmaceuticals, Inc. (KERX) and Lipocine Inc. (NASDAQ:LPCN)

Analysts are eager to weigh in on biotech giant Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) after new earnings results and Lipocine Inc.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts